TerminatedPhase 2NCT00230334

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

Studying Hypereosinophilic syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Steven E. Coutre
Principal Investigator
Steven E Coutre
Stanford University
Intervention
Gleevec(drug)
Enrollment
5 enrolled
Eligibility
18 years · All sexes
Timeline
20032007

Study locations (1)

Collaborators

Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00230334 on ClinicalTrials.gov

Other trials for Hypereosinophilic syndrome

Additional recruiting or active studies for the same condition.

See all trials for Hypereosinophilic syndrome

← Back to all trials